General Summary The Research Assistant (RA) will be a member of the Center for the Evaluation of Value and Risk in Health (CEVR), which is part of the...
Read moreThe Data Scientist will be a member of the Center for the Evaluation of Value and Risk in Health (CEVR), which is part of the Institute for Clinical R...
Read moreWe are pleased to announce a post-doctoral fellow position at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center...
Read moreLin, PJ, Cohen, JT, Neumann, PJ. Preparing the health‐care system to pay for new Alzheimer's drugs. Alzheimer's Dement. 2020; 1– 3.
Ma S, Kim DD, Cohen JT, Neumann PJ. "Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China," Value in Health (in press).
Kim, DD, Silver, MC, Kunst, N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974–2018. PharmacoEconomics 38, 1135–1145 (2020).
Xue F, Berklein F, Rane PB, Habib M, Lin PJ. "Patient characteristics and treatment patterns among Medicare beneficiaries initiating PCSK9 inhibitor therapy," Cardiovascular Drugs and Therapy, June 27, 2020.
Kim DD, Ollendorf DA, Neumann PJ, Fendrick M. "Crisis into opportunity: Can COVID-19 help set a path to improved health care efficiency?,"AJMC Commentary, June 17, 2020.
Forsythe S, Cohen J, Neumann P, Bertozzi SM, Kinghorn A. “The economic and public health imperatives around making potential coronavirus disease-2019 treatments available and affordable,” Value in Health, May 21, 2020.
Cohen JT, Neumann PJ, Ollendorf DA. "Valuing and pricing Remdesivir: Should drug makers get paid for helping us get back to work?," Health Affairs Blog, May 20, 2020.
Kim DD, Neumann PJ. "Analyzing the cost effectiveness of policy responses for COVID-19: The importance of capturing social consequences," Medical Decision Making Research Letter, May 19, 2020.
Chambers JD, Lai RC, Margaretos NM, Panzer AD, Cohen JT, Neumann PJ. "Coverage for Biosimilars vs reference products among US commercial health plans," Journal of the American Medical Association Research Letter, May 19, 2020.
Panzer AD, Emerson JG, D'Cruz B, Patel A, Dabak S, Isaranuwatchai W, Kim DD. "Growth and capacity for cost‐effectiveness analysis in Africa," Health Economics Letter, May 15, 2020.
Leech AA, Neumann PJ, Cohen JT, Jagasia M, Dusetzina SB. Balancing value with affordability: Cell immunotherapy for cancer treatment in the U.S. The Oncologist 2020.
Olchanski N, Vest AR, Cohen JT, Denofrio D. Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission. International Journal of Cardiology 2020;307:109–13.
Feng X, Kim DD, Cohen JT, Neumann PJ, Ollendorf DA. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter? International Journal of Technology Assessment in Health Care 2020;:1–8.
Panzer AD, Margaretos NM, Lai RC, Enright DE, Chambers JD. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions? Pharmacoepidemiology and Drug Safety 2020;1–5.
Lin PJ, Emerson J, Faul JD, Cohen JT, Neumann PJ, Fillit HM, Daly AT, Margaretos N, Freund KM. Racial and ethnic differences in knowledge about one's dementia status. Journal of the American Geriatrics Society (in press).
Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.
Meet the CEVR TeamOur comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.
The CEA Registry is a comprehensive database of 5,655 cost-utility analyses on a wide variety of diseases and treatments.
View RegistryThe GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.
View RegistryThe Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.
View Database